Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease – Pipeline Review, H2 2016, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10, 5, 46 and 17 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 19 and 4 molecules, respectively.Huntington Disease.
Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Addex Therapeutics Ltd
AFFiRiS AG
Angita BV
Annexon Inc
Astellas Pharma Inc
Azevan Pharmaceuticals Inc
BioCrea GmbH
BrainStorm Cell Therapeutics Inc
Celon Pharma Sp z oo
Chong Kun Dang Pharmaceutical Corp
Diffusion Pharmaceuticals Inc
EncephRx Inc
Evotec AG
Galenea Corp
Genervon Biopharmaceuticals LLC
Horizon Pharma Plc
Immungenetics AG
Ionis Pharmaceuticals Inc
Ipsen SA
Kadmon Corp LLC
KineMed Inc
Krenitsky Pharmaceuticals Inc
Living Cell Technologies Ltd
Medesis Pharma SA
Mitochon Pharmaceuticals Inc
Neuralstem Inc
Neurimmune Holding AG
NeuroNascent Inc
New World Laboratories Inc
nLife Therapeutics SL
NsGene A/S
Omeros Corp
Oryzon Genomics SA
Pfizer Inc
PharmatrophiX Inc
ProQR Therapeutics NV
QR Pharma Inc
reMYND NV
Retrotope Inc
Rhenovia Pharma Ltd
Shire Plc
SOM Biotech SL
Spark Therapeutics Inc
Teva Pharmaceutical Industries Ltd
TyrNovo Ltd
Ultragenyx Pharmaceutical Inc
UniQure NV
Vaccinex Inc
Vertex Pharmaceuticals Inc
VistaGen Therapeutics Inc
Vitality Biopharma Inc
VivaCell Biotechnology Espana SL
Voyager Therapeutics Inc
Vybion Inc
WAVE Life Sciences Ltd
Wellstat Therapeutics Corp
'
Table of Contents
Table of Contents 2
Introduction 5
Huntington Disease Overview 6
Therapeutics Development 7
Huntington Disease - Therapeutics under Development by Companies 9
Huntington Disease - Therapeutics under Investigation by Universities/Institutes 13
Huntington Disease - Pipeline Products Glance 15
Huntington Disease - Products under Development by Companies 18
Huntington Disease - Products under Investigation by Universities/Institutes 23
Huntington Disease - Companies Involved in Therapeutics Development 24
Huntington Disease - Therapeutics Assessment 80
Drug Profiles 91
Huntington Disease - Dormant Projects 260
Huntington Disease - Discontinued Products 268
Huntington Disease - Product Development Milestones 269
Appendix 279
List of Tables
Number of Products under Development for Huntington Disease, H2 2016 19
Number of Products under Development for Huntington Disease - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Number of Products under Development by Companies, H2 2016 (Contd..2) 23
Number of Products under Development by Companies, H2 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Development, H2 2016 29
Products under Development by Companies, H2 2016 30
Products under Development by Companies, H2 2016 (Contd..1) 31
Products under Development by Companies, H2 2016 (Contd..2) 32
Products under Development by Companies, H2 2016 (Contd..3) 33
Products under Development by Companies, H2 2016 (Contd..4) 34
Products under Investigation by Universities/Institutes, H2 2016 35
Huntington Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 36
Huntington Disease - Pipeline by AFFiRiS AG, H2 2016 37
Huntington Disease - Pipeline by Angita BV, H2 2016 38
Huntington Disease - Pipeline by Annexon Inc, H2 2016 39
Huntington Disease - Pipeline by Astellas Pharma Inc, H2 2016 40
Huntington Disease - Pipeline by Azevan Pharmaceuticals Inc, H2 2016 41
Huntington Disease - Pipeline by BioCrea GmbH, H2 2016 42
Huntington Disease - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 43
Huntington Disease - Pipeline by Celon Pharma Sp z oo, H2 2016 44
Huntington Disease - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 45
Huntington Disease - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 46
Huntington Disease - Pipeline by EncephRx Inc, H2 2016 47
Huntington Disease - Pipeline by Evotec AG, H2 2016 48
Huntington Disease - Pipeline by Galenea Corp, H2 2016 49
Huntington Disease - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 50
Huntington Disease - Pipeline by Horizon Pharma Plc, H2 2016 51
Huntington Disease - Pipeline by Immungenetics AG, H2 2016 52
Huntington Disease - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 53
Huntington Disease - Pipeline by Ipsen SA, H2 2016 54
Huntington Disease - Pipeline by Kadmon Corp LLC, H2 2016 55
Huntington Disease - Pipeline by KineMed Inc, H2 2016 56
Huntington Disease - Pipeline by Krenitsky Pharmaceuticals Inc, H2 2016 57
Huntington Disease - Pipeline by Living Cell Technologies Ltd, H2 2016 58
Huntington Disease - Pipeline by Medesis Pharma SA, H2 2016 59
Huntington Disease - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 60
Huntington Disease - Pipeline by Neuralstem Inc, H2 2016 61
Huntington Disease - Pipeline by Neurimmune Holding AG, H2 2016 62
Huntington Disease - Pipeline by NeuroNascent Inc, H2 2016 63
Huntington Disease - Pipeline by New World Laboratories Inc, H2 2016 64
Huntington Disease - Pipeline by nLife Therapeutics SL, H2 2016 65
Huntington Disease - Pipeline by NsGene A/S, H2 2016 66
Huntington Disease - Pipeline by Omeros Corp, H2 2016 67
Huntington Disease - Pipeline by Oryzon Genomics SA, H2 2016 68
Huntington Disease - Pipeline by Pfizer Inc, H2 2016 69
Huntington Disease - Pipeline by PharmatrophiX Inc, H2 2016 70
Huntington Disease - Pipeline by ProQR Therapeutics NV, H2 2016 71
Huntington Disease - Pipeline by QR Pharma Inc, H2 2016 72
Huntington Disease - Pipeline by reMYND NV, H2 2016 73
Huntington Disease - Pipeline by Retrotope Inc, H2 2016 74
Huntington Disease - Pipeline by Rhenovia Pharma Ltd, H2 2016 75
Huntington Disease - Pipeline by Shire Plc, H2 2016 76
Huntington Disease - Pipeline by SOM Biotech SL, H2 2016 77
Huntington Disease - Pipeline by Spark Therapeutics Inc, H2 2016 78
Huntington Disease - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 79
Huntington Disease - Pipeline by TyrNovo Ltd, H2 2016 80
Huntington Disease - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2016 81
Huntington Disease - Pipeline by UniQure NV, H2 2016 82
Huntington Disease - Pipeline by Vaccinex Inc, H2 2016 83
Huntington Disease - Pipeline by Vertex Pharmaceuticals Inc, H2 2016 84
Huntington Disease - Pipeline by VistaGen Therapeutics Inc, H2 2016 85
Huntington Disease - Pipeline by Vitality Biopharma Inc, H2 2016 86
Huntington Disease - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 87
Huntington Disease - Pipeline by Voyager Therapeutics Inc, H2 2016 88
Huntington Disease - Pipeline by Vybion Inc, H2 2016 89
Huntington Disease - Pipeline by WAVE Life Sciences Ltd, H2 2016 90
Huntington Disease - Pipeline by Wellstat Therapeutics Corp, H2 2016 91
Assessment by Monotherapy Products, H2 2016 92
Number of Products by Stage and Target, H2 2016 94
Number of Products by Stage and Mechanism of Action, H2 2016 97
Number of Products by Stage and Route of Administration, H2 2016 100
Number of Products by Stage and Molecule Type, H2 2016 102
Huntington Disease - Dormant Projects, H2 2016 272
Huntington Disease - Dormant Projects (Contd..1), H2 2016 273
Huntington Disease - Dormant Projects (Contd..2), H2 2016 274
Huntington Disease - Dormant Projects (Contd..3), H2 2016 275
Huntington Disease - Dormant Projects (Contd..4), H2 2016 276
Huntington Disease - Dormant Projects (Contd..5), H2 2016 277
Huntington Disease - Dormant Projects (Contd..6), H2 2016 278
Huntington Disease - Dormant Projects (Contd..7), H2 2016 279
Huntington Disease - Discontinued Products, H2 2016 280
List of Figures
Number of Products under Development for Huntington Disease, H2 2016 19
Number of Products under Development for Huntington Disease - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Products, H2 2016 29
Assessment by Monotherapy Products, H2 2016 92
Number of Products by Top 10 Targets, H2 2016 93
Number of Products by Stage and Top 10 Targets, H2 2016 93
Number of Products by Top 10 Mechanism of Actions, H2 2016 96
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 96
Number of Products by Top 10 Routes of Administration, H2 2016 99
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 99
Number of Products by Top 10 Molecule Types, H2 2016 101
Number of Products by Stage and Top 10 Molecule Types, H2 2016 101
